# Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

> **NCT04894643** · NA · RECRUITING · sponsor: **EBG MedAustron GmbH** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Cancer
- Proton Therapy

## Interventions

- **RADIATION:** Proton Ions
- **DRUG:** Nab-PACLitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine
- **PROCEDURE:** Surgical resection of the pancreas (when feasible)

## Key facts

- **NCT ID:** NCT04894643
- **Lead sponsor:** EBG MedAustron GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- Landesklinkum Wiener Neustadt

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894643, "Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04894643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*